An observational study in Aging, Polypharmacy and Malnutrition, sponsored by Hvidovre University Hospital. Recruiting at 1 site in Denmark. Open to participants aged 20 Years to 110 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Hvidovre University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Malnutrition with a site in Denmark — 8 open to participants now, 10 under way, none of them phase 3. Malnutrition · Denmark.
Among the 42 studies in Malnutrition with a site in Denmark, this one is the only one that started in 2016, is one of 7 observational ones, and was the 17th registered.
1,278 studies on the registry are indexed under Malnutrition; 231 are open to participants now.
Browse Malnutrition studies →8 of the 42 studies in Malnutrition with a site in Denmark are open now. Recruiting first, the newest first:
Bispebjerg Hospital · Sites in Denmark
Ages 65+
Bispebjerg Hospital · Sites in Denmark
Ages 65+
Herlev and Gentofte Hospital · Sites in Denmark
Ages 50+
Bispebjerg Hospital · Sites in Denmark
Ages 18+
Bispebjerg Hospital · Sites in Denmark
Ages 18–100
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 150 Malnutrition studies recruiting now, 84 (56%) set no upper age limit and 44 (29%) stop at 75 or younger; 40 take children under 18; 30 take healthy volunteers.
This study: 20 Years to 110 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 212 is close to the median of 206 across 393 observational studies indexed under Malnutrition.
Median enrollment 48 across the 35 interventional studies, 62 across the 7 observational. Of the 27 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 42 has an industry lead sponsor. The 10 most frequent:
Hvidovre University Hospital is the lead sponsor of 299 studies on the registry; 20 are open to participants now.
Hvidovre University Hospital has 5 studies filed under Malnutrition — fewer than ten, so there is no comparison to draw.
2 of the studies in Malnutrition with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06946537Bispebjerg HospitalNutritional Status and Patient Characteristics Upon Length of Stay, Clinical Outcome, and Survival in Older Hospitalized Patients | 2027-04 |
| NCT07373587Bispebjerg HospitalPreventing Hospital Associated Disability in Older Patients: Individualized Nutrition and Exercise Strategy | 2027-09-28 |
Add all 2 to your calendar (.ics) → With an account.
Among the 42 studies in Malnutrition with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In this study, the investigators will investigate and characterize acute medical patients in order to optimize patient courses in the acute care departments, especially with regard to polypharmacy and undernourishment. In addition, the investigators will investigate underlying immunological mechanisms of chronic inflammation and biological aging in this population to improve the current knowledge and possibilities for preventing chronic diseases and acute hospitalization.
Malnutrition:
Malnutrition among elderly is associated with frailty, including loss of weight, muscle mass, function and quality of life and also with an increased number of hospital admissions. In this study, the investigators aim to describe the development of and the risk factors for malnutrition from admission to 4 weeks after discharge, in addition the investigators wish to characterize the inflammatory state of the malnourished patients.
Inappropriate polypharmacy:
The broad variation among elderly in health, number of chronic diseases, organ function, biological age and function makes the prescription of drugs to this population a very complex task with a high risk of inappropriate medication. 5-30% of all non-elective admissions are caused by inappropriate medications, and many of these are preventable. Therefore, the investigators aim to investigate the feasibility of a pharmacist-geriatrician medication review in the acute care department and the effect on the Medication Appropriateness Index score (MAI-score) .
Chronic inflammation and biological aging:
Chronic inflammation and biological aging promote the development of age-related chronic diseases. There is a large variation in the rate of aging between individuals, in particular among the elderly. This means that the chronological age of a person often does not reflect its true state of aging, the biological age. This challenges the ability to provide appropriate care and to predict responses to treatment and interventions in elderly patients. The underlying causes and mechanisms of biological aging and chronic inflammation are not well understood. There are currently no validated methods for measuring biological age and no measures of chronic inflammation which can be used in an acute setting. Here, the investigators aim to test a novel model for chronic inflammation and investigate the role of the NLRP3 inflammasome, NFkB (nuclear factor kappa light chain enhancer of activated B cells) and miRNAs in biological aging and chronic inflammation.
The study is prospective with 3 groups of study participants: one group is included in the Acute Medical Department and two healthy control groups (one young and one older). The follow-up comprises two predefined examinations and any readmissions at our hospital. Furthermore, participants are followed in the national registries.
Three study groups; the FAM group, control group 1 and control group 2
FAM group:
Inclusion Criteria:
Exclusion Criteria:
Control group 1:
Inclusion Criteria:
Exclusion Criteria:
Control group 2:
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
≥65 years. Acutely admitted medical patients. Included consecutively at admission to the Acute Medical Department at Amager and Hvidovre Hospital and Rigshospitalet - Glostrup. Follow-up at 4 weeks and 56 weeks after discharge and at any readmissions in the study period. Participants are interviewed on physical, mental and nutritional status, tested for functional and cognitive status, and have anthropometry, biochemistry, blood pressure, and immune activity measured. Participants are followed in national registries for information on diagnoses, hospital admissions, health care services used, and mortality. If a patient uses ≥5 prescribed drugs before hospitalization, a medication review will be performed by a clinical pharmacist and a geriatrician. Sample size calculations were performed for each primary outcome, and the final sample size was based on the calculation for the eating validation scheme which resulted in the largest sample size.
≥65 years. No hospital admissions within the past two years. Matched individually with patients in the FAM group by age, sex, and municipality. Examined at inclusion and 52 weeks after inclusion. Participants are interviewed on physical, mental and nutritional status, tested for functional and cognitive status, and have anthropometry, biochemistry, blood pressure, and immune activity measured. Participants are followed in national registries for information on diagnoses, hospital admissions, health care services used, and mortality.
20-35 years No admissions due to chronic or critical illness within the past 5 years (except admissions related to child birth, abortion, appendicitis, poisoning, traumas, concussion etc.) Examined at inclusion and 4 weeks after inclusion. The examination includes a questionnaire about life style, a physical examination, and blood samples.
Eating validation scheme score
Development in nutritional status and risk factors of malnutrition within the FAM group.
Time frame: From inclusion to 4 weeks after discharge
MAI score (Medication Appropriateness Index)
Difference in summed MAI-score per patient. MAI score between inclusion and first follow-up visit (FAM group)
Time frame: From inclusion to 4 weeks after discharge
NF-kB (Nuclear Factor Kappa light chain enhancer og activated B cells) activity
The development in NF-kB activity between the groups will be investigated. The association of NF-kB activity with biological ageing-measured by chronic inflammation, and loss of function and cognition-will also be investigated.
Time frame: From inclusion to 56 weeks after discharge
Chronic inflammation
Stability and discriminative ability of new model for chronic inflammation (Control group 2)
Time frame: From inclusion to 4 weeks after inclusion
NLRP3 activity
Difference in NLRP3 inflammasome activity between groups.
Time frame: From inclusion to 56 weeks after discharge
Bodyweight (kg)
Development in bodyweight
Time frame: From inclusion to 4 and 56 weeks after discharge
Health related Quality of life
Assessed with EQ-5D-5L(EuroQol-5Dimentions-5Llevels) and mini geriatric depression score
Time frame: From inclusion to 56 weeks after discharge
Medication under-prescribing
Assessment of underutilization Index (AOU)
Time frame: From inclusion to 4 weeks after discharge
Inflammation in malnourished patients
Characterize the level of inflammation in malnourished patients
Time frame: 4 weeks after discharge
Functional recovery score
Assessing activities of daily living to characterize development in physical performance
Time frame: From inclusion to 56 weeks after discharge
Cystatin C
Cystatin C
Time frame: From inclusion to 56 weeks after discharge
Cytokine concentrations
The concentration of cytokines at baseline and in response to stimulation will be measured
Time frame: From inclusion to 56 weeks after discharge
Cytometry
Characterization of immune cell subsets
Time frame: From inclusion to 56 weeks after discharge
miRNA
Levels of miRNA will be measured, and their association with NF-kB activity and biological ageing will be investigated.
Time frame: From inclusion to 56 weeks after discharge
NF-kB activation
The activation of NF-kB in response to stimulation.
Time frame: From inclusion to 56 weeks after discharge
C-reactive protein (inflammation)
Difference in inflammation between groups
Time frame: From inclusion to 56 weeks after discharge
Soluble urokinase plasminogen activator receptor (suPAR) (ng/ml)
The plasma level of suPAR is a measure of inflammation and can be used to assess the difference in inflammation between groups
Time frame: From inclusion to 56 weeks after discharge
Frequency of physicians' acceptance of suggested changes in medications
Frequency of physicians' acceptance of suggested changes in medications
Time frame: At inclusion and at 4 weeks after discharge in the FAM group
Sit-to-stand test
Development in physical performance
Time frame: From inclusion to 56 weeks after discharge
Cognitive functional ability
Orientation memory concentration, mini mental state examination, Hopkins verbal learning test, trail making test, digit symbol substitution test
Time frame: From inclusion to 56 weeks after discharge
Waist circumference (cm)
Waist circumference (cm)
Time frame: From inclusion to 56 weeks after discharge
Handgrip strength (kg) of dominant hand
Development in physical performance
Time frame: From inclusion to 56 weeks after discharge
Habitual 4 m gait speed (m/s)
Development in physical performance
Time frame: From inclusion to 56 weeks after discharge
Plasma and serum concentrations of admission blood samples
Routinely analyzed physiological biomarkers measured in plasma and serum
Time frame: From inclusion to 56 weeks after discharge
Blood concentration of cholesterol and triglycerides
Blood concentration of cholesterol and triglycerides
Time frame: From inclusion to 56 weeks after discharge
Blood concentration of metabolic markers
Measurement of insulin, blood glucose, and HbA1c
Time frame: From inclusion to 56 weeks after discharge
Plasma concentration of active drug substances
Plasma concentration of active drug substances
Time frame: From inclusion to 56 weeks after discharge
CMV-IgG (Cytomegalovirus-immunoglobulin G)
Cytomegalovirus IgG titer
Time frame: From inclusion to 56 weeks after discharge
Plan to share: No
Started Nov 2016 (actual). Primary completion is estimated for Oct 2031, 179 months after the start.
Of 175 non-industry observational studies under Malnutrition, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 41. This study's planned 179 months is above that.
Counting every sponsor, half of 187 studies reached it within 21 months; a quarter within 11 and three quarters within 41.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Dec 2019 → Oct 2031 and completion Dec 2019 → Oct 2031.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hvidovre University Hospital →